- Home
- CISS vs PPBT Comparison
CISS vs PPBT Comparison
Compare CISS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- PPBT
- Stock Information
- Founded
- CISS 2022
- PPBT 2010
- Country
- CISS Greece
- PPBT Israel
- Employees
- CISS N/A
- PPBT N/A
- Industry
- CISS Marine Transportation
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- PPBT Health Care
- Exchange
- CISS Nasdaq
- PPBT Nasdaq
- Market Cap
- CISS 2.5M
- PPBT 2.1M
- IPO Year
- CISS N/A
- PPBT N/A
- Fundamental
- Price
- CISS $2.65
- PPBT $0.60
- Analyst Decision
- CISS
- PPBT Strong Buy
- Analyst Count
- CISS 0
- PPBT 1
- Target Price
- CISS N/A
- PPBT $33.00
- AVG Volume (30 Days)
- CISS 319.3K
- PPBT 2.9M
- Earning Date
- CISS 09-02-2025
- PPBT 11-14-2025
- Dividend Yield
- CISS N/A
- PPBT N/A
- EPS Growth
- CISS N/A
- PPBT N/A
- EPS
- CISS 5.74
- PPBT N/A
- Revenue
- CISS $38,084,901.00
- PPBT N/A
- Revenue This Year
- CISS N/A
- PPBT N/A
- Revenue Next Year
- CISS N/A
- PPBT N/A
- P/E Ratio
- CISS $0.39
- PPBT N/A
- Revenue Growth
- CISS N/A
- PPBT N/A
- 52 Week Low
- CISS $2.03
- PPBT $0.53
- 52 Week High
- CISS $18.75
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- CISS 47.52
- PPBT 32.32
- Support Level
- CISS $2.18
- PPBT N/A
- Resistance Level
- CISS $3.80
- PPBT $2.36
- Average True Range (ATR)
- CISS 0.18
- PPBT 0.14
- MACD
- CISS 0.00
- PPBT -0.10
- Stochastic Oscillator
- CISS 58.49
- PPBT 25.54
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.